Avanos Medical (NYSE:AVNS - Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 1.300-1.350 for the period, compared to the consensus estimate of 1.390. The company issued revenue guidance of $683.0 million-$688.0 million, compared to the consensus revenue estimate of $695.2 million.
Analyst Ratings Changes
Separately, StockNews.com raised Avanos Medical from a "buy" rating to a "strong-buy" rating in a research note on Saturday.
View Our Latest Report on AVNS
Avanos Medical Trading Down 17.8 %
Shares of Avanos Medical stock traded down $4.03 on Wednesday, hitting $18.60. 333,813 shares of the company's stock traded hands, compared to its average volume of 235,895. Avanos Medical has a one year low of $17.39 and a one year high of $25.36. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.28 and a quick ratio of 1.49. The company has a fifty day moving average of $23.41 and a two-hundred day moving average of $21.52. The company has a market capitalization of $854.65 million, a price-to-earnings ratio of -15.33 and a beta of 0.91.
Avanos Medical (NYSE:AVNS - Get Free Report) last announced its earnings results on Wednesday, July 31st. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.29 by $0.05. Avanos Medical had a return on equity of 4.48% and a net margin of 1.13%. The company had revenue of $171.70 million for the quarter, compared to analyst estimates of $170.67 million. During the same quarter in the prior year, the company earned $0.24 EPS. The firm's revenue for the quarter was up 1.4% compared to the same quarter last year. As a group, sell-side analysts expect that Avanos Medical will post 1.39 earnings per share for the current year.
Avanos Medical Company Profile
(
Get Free Report)
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
Further Reading
Before you consider Avanos Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avanos Medical wasn't on the list.
While Avanos Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
